Shares of United Therapeutics UTHR are trading sharply higher on news that patent infringement ruling against competitor Sandoz.
The ruling disallows Sandoz to sell the generic version of United Therapeutics hypertension drug Remodulin before 2017.
Shares were trading up more than 24 percent to $114.47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in